Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Trump rolls out Medicaid drug pricing deal for all 50 states. President Trump announced a "most favored nation" drug pricing arrangement for state Medicaid programs, projected to save states $27.6 billion and the federal government $36.6 billion. The deal covers hundreds of brand-name drugs, but critics say key details remain hidden and question whether pharmaceutical companies will actually follow through.
Trump rolls out Medicaid drug pricing deal for all 50 states
President Trump announced a sweeping drug pricing arrangement that would extend "most favored nation" prices to all 50 state Medicaid programs. Under the deal, participating pharmaceutical companies would provide rebates on selected brand-name drugs, ensuring Medicaid pays no more than what other developed countries pay. The agreement spans hundreds of drugs across major therapeutic areas, including oncology, diabetes, and asthma.
The White House and the Council of Economic Advisers project combined savings of over $64 billion — $27.6 billion for states and $36.6 billion federally. Trump is touting the arrangement as a signature healthcare win ahead of the midterm elections, with CMS Administrator Mehmet Oz calling it "better value for taxpayers." Critics, however, argue that key pricing details remain confidential and that drug companies have yet to demonstrate meaningful follow-through on commitments to lower U.S. launch prices.
By the Numbers
Why it matters: Medicaid prescription drug spending has surged in recent years — driven by pricey GLP-1s, cell therapies, and gene therapies. With key pricing details kept confidential and significant skepticism from watchdog groups, the real-world impact on drug costs and patient access remains to be seen.
